Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | FORTE update: carfilzomib-lenalidomide induction therapy for MM

Francesca Gay • 1 Jun 2018
ASCO 2018
Multiple Myeloma Carfilzomib Cyclophosphamide Dexamethasone Lenalidomide
FORTE

Francesca Gay, MD, of the University of Torino, Torino, Italy, provides an efficacy data update from the FORTE trial (NCT02203643), which investigated carfilzomib plus lenalidomide or cyclophosphamide for the treatment of newly diagnosed multiple myeloma (MM) prior to transplant. She highlights complete response rates with both regimens, as well as the results of MRD analysis. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

More from Francesca Gay

1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay • 7 Dec 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals